
Wynn Inaugurates Special Exhibition "The Odyssey of Jingdezhen Porcelain: A Heritage Voyage from Macao to the World"
Guests officiating at the opening ceremony included: Vice-chairman of the National Committee of the Chinese People's Political Consultative Conference, Mr. Ho Hau Wah; Director of the Department of Publicity and Culture of the Liaison Office of the Central People's Government in the Macao SAR, Mr. Wan Sucheng; Director of the Department of Information and Public Diplomacy of the Ministry of Foreign Affairs in the Macao SAR, Mr. Gao Yuan; President of the Cultural Affairs Bureau of the Macao SAR Government, Ms. Leong Wai Man; President of the Administrative Committee of the Macao Foundation, Mr. Wu Zhiliang; Deputy Consul for Education and Culture at the Consulate General of Portugal in Macao and Hong Kong, Dra. Patricia Quaresma; Deputy Secretary-General of the Permanent Secretariat of the Forum for Economic and Trade Co-operation between China and Portuguese-speaking Countries (Macao), Mr. António Lei; Deputy Director of the Macao Government Tourism Office, Mr. Cheng Wai Tong; General Manager of Jiangxi Media Group, Mr. Han Xingwen; President of Macau Chinese Cultural Friendship Association, Mr. Leong Wa; Head of the Department of Students of the Education and Youth Development Bureau of the Macao SAR Government, Mr. Chan Iok Wai; President, Vice Chairman and Executive Director of Wynn Macau, Limited, Ms. Linda Chen; and Deputy Director of Jingdezhen Municipal Bureau of Culture, Radio, Television, Publication and Tourism, Mr. Zhan Xinghua. In the presence of all the guests, the officiating dignitaries held porcelain pieces and aligned them together perfectly during the countdown, symbolizing that "porcelain pieces reunite, civilization revives!" and inaugurating exhibition 'Hello China, Hello Macao – The Odyssey of Jingdezhen Porcelain: A Heritage Voyage from Macao to the World."
Ms. Leong Wai Man stated in her speech that this exhibition is not only a cultural feast presented by Wynn Macau but also a pioneering initiative under the SAR Government's "government-enterprise collaboration" model to promote Chinese culture innovatively. It responds to the nomination of Jingdezhen's handmade porcelain heritage sites for the UNESCO World Heritage List and leaves a vibrant mark on Macao, "a base for exchange and cooperation where Chinese culture is the mainstream and diverse cultures coexist." By recreating the blue-and-white and ink wash painting styles of ceramics with digital art and reinvigorating historical narratives with projection technology, the exhibition realizes the "creative transformation and innovative development of outstanding Chinese traditional culture." Moreover, this collaboration has also built a bridge for cultural and tourism cooperation between Jiangxi and Macao, allowing porcelain, a carrier of Chinese civilization, to continue its mission as a cultural messenger in the new era.
Wynn Macau's meticulous efforts demonstrate the company's outstanding vision in fulfilling cultural responsibility. Every artwork featured in the exhibition reflects the curatorial team's dedication, particularly their reverence for the roots of civilization. We hope to take today's exhibition as a starting point to continue working together on the broad platform of "Art Macao," collaboratively exploring pathways for Chinese culture to reach the world and co-creating an artistic stage where diverse cultures coexist harmoniously.
Ms. Linda Chen said that Wynn is joining hands with Jingdezhen of Jiangxi Province to present the world's first large-scale immersive art exhibition featuring porcelain from Jingdezhen. Reinvigorating traditional aesthetics with modern technology, this exhibition offers residents and tourists a brand-new perspective featuring a 360-degree immersive experience of the beauty of imperial kiln treasures from the Qing Dynasty. Moreover, the exhibition unprecedentedly integrates the artworks of state-level masters, showcasing a feast of blossoming contemporary Chinese ceramic art to the world.
Wynn launched the new cultural brand "Wynn Culture" this year with the goal of "promoting outstanding Chinese traditional culture and fostering mutual exchange and appreciation between diverse civilizations" and to further deepen Macao's strategic position as a "base for exchange and cooperation where Chinese culture is the mainstream and diverse cultures coexist." Wynn Culture is not an isolated brand, but an important organic component of "Art Macao" as a grand narrative. Wynn Culture adheres to three core principles: upholding integrity and innovation, engaging in dialogue with the world, and passing on traditions, and taking its root in Macao, a link for Chinese and Western cultural exchange. The brand is dedicated to telling China's stories well, constantly strengthening Macao's unique role as a hub for domestic and foreign connections, and showcasing the cultural confidence of the Chinese nation to the world.
Mr. Han Xingwen stated that this exhibition is not only a cultural showcase but also an effectual initiative for Jiangxi and Macao to further the practice of "One Country, Two Systems" and promote cultural exchange and industrial cooperation. He reflected on the historical fact that in 1603, a Portuguese ship loaded with Clark porcelain set sail from Macao, which went on to become a cultural symbol for Europe's understanding of China. He stated that the digital representation of the history reveals the eternal theme of mutual appreciation among civilizations, perfectly aligning with the collaborative philosophy of "complementary advantages and equal cooperation" between Jiangxi and Macao. It deeply integrates Jiangxi's "advantages in cultural resources" with Macao's role as an "international communication hub," marking a new starting point and significant milestone for digital cultural cooperation between the two regions.
Renowned Chinese artist, designer and educator Master Chang Shana is invited to serve as the chief aesthetic advisor for the exhibition. Master Chang has been a leading designer for the Great Hall of the People, the former president of the Central Academy of Arts and Crafts, and a member of the Seventh, Eighth and Ninth Standing Committee of the National People's Congress and named among the Artists with Lifelong Achievements by the China Federation of Literary and Art Circles. At the opening ceremony, Master Chang gifted her work Peace Dove to Wynn, making Wynn another organization which boasts her masterpiece as part of its permanent collection in addition to other major cultural institutions in China. She recorded a special video to wish this Special Exhibition of Wynn a great success.
The exhibition "Hello China, Hello Macao – The Odyssey of Jingdezhen Porcelain: A Heritage Voyage from Macao to the World" comprises a digital exhibition and an art exhibition. The digital exhibition recreates elements such as the history of ceramics, Maritime Silk Road in Macao, and imperial kiln masterpieces from Qing Dynasty with newly crafted, 360-degree immersive projections, comprehensively showcasing the history of how Jingdezhen has played a leading role in ceramic crafting techniques worldwide. The art exhibition features the first overseas debut of Peace Dove, an inaugural national gift designed by Master Chang Shana for the People's Republic of China, as well as artworks by over 30 national and contemporary craft masters, including Lu Ru, Ning Gang, Liu Wei, Huang Jingzang, and Liu Wenbin. The exhibition also presents the four renowned porcelain varieties from Jingdezhen and their exquisite craftsmanship; Clark porcelain, which reflects traits of Sino-Portuguese cultural exchange; and the Buccleuch Vases from the exceptional art collection at Wynn, an epic masterpiece set that embodies the fusion of Eastern and Western art.
A welcome banquet was also held for the "Art Macao: Macao International Art Biennale 2025" at the Grand Theater Ballroom at Wynn Palace on the same evening. The banquet for this cultural extravaganza pushed creativity to its peak, artfully constructing a platform to promote the culture of Jiangxi. Each dish carried profound connotations, echoing the artistic conception of one of the ceramic masters' works featured in Wynn's special exhibition. The integrated design of "one dish, one local specialty, one exquisite vessel" transformed every flavor into a vivid ambassador of Jiangxi Province. The tangible, perceivable, and palatable cultural experiences artfully transformed Jiangxi's abundant resources and the millennial craftsmanship of its porcelain capital into distinct cultural symbols. As such, Wynn has built a bridge connecting Jiangxi's treasures to the world, allowing guests from around the globe to appreciate Jiangxi's unique natural and cultural riches through an immersive feast of taste and vision, successfully propelling the province's cultural and industrial best onto a wider global stage.
In addition to the exhibition, a seminar titled "Silk Road Ceramic Journey • Macau's New Chapter" will also be held on July 19 to intensify cooperation in cultural tourism between Jingdezhen, Macao and the international community. Using the ceramic culture of Jingdezhen as a link, the seminar will build an international platform for the mutual exchange and appreciation between Chinese and foreign civilizations and help the world-renowned "ceramic culture" of Jingdezhen, Jiangxi to set sail from Macao to the wider global stage.
The Special Exhibition "Hello China, Hello Macao – The Odyssey of Jingdezhen Porcelain: A Heritage Voyage from Macao to the World" is curated by Wynn for Art Macao under the patronage of the Secretariat for Social Affairs and Culture of the Macao SAR and with the support from the Permanent Secretariat of the Forum for Economic and Trade Co-operation between China and Portuguese-speaking Countries (Macao), Macao Government Tourism Office, Commerce and Investment Promotion Institute of the Macao SAR, and Chinese People's Political Consultative Conference Jingdezhen Municipal Committee, Jiangxi Province. The exhibition is organized by Wynn Resorts Macau and the Jingdezhen Municipal Bureau of Culture, Radio, Television, Publication and Tourism, with the Federation of Associations of Cultural Sectors of Macau as the joint organizer; the Cultural Affairs Bureau of the Macao SAR, member of the Jiangxi Provincial Committee of the Chinese People's Political Consultative Conference from the Macao SAR, Jingdezhen Municipal Committee of China National Democratic Construction Association, Jingdezhen China Ceramics Museum, Classic of Mountain and Sea Research Institute and Jiangxi Fellow Association of Macau as co-organizers; Macau Lotus TV Limited, Jiangxi Province Digital Culture Group and Jingdezhen Art Museum as implementers; and with academic support from the City University of Macau. The exhibition is open to the public with free admission at the Illuminarium and the Palace Reserve Club Gallery at Wynn Palace from 11 a.m. to 7 p.m. every Tuesday to Sunday between July 19 and October 19, 2025.
Media Photos:
Hi-Res photo download link: Here
ABOUT WYNN MACAU
Wynn Macau is a luxury hotel and integrated resort in the Macau Special Administrative Region of the People's Republic of China with two iconic towers featuring a total of 1,010 spacious rooms and suites, approximately 64,500 square feet of retail space, 9 food and beverage outlets, two spas, a salon and a pool. The resort proudly boasts three distinct entertainment experiences, including Macau's only choreographed Performance Lake, blending lofty plumes of water, gracefully choreographed music from Broadway tunes to renowned Chinese songs, powerful LED lights and fire effects.
Wynn Macau is operated by international resort developer Wynn Resorts, recipient of more Forbes Travel Guide Five Star Awards than any other independent hotel company in the world. Wynn Macau is the only resort worldwide with 6 Forbes Travel Guide Five-Star Awards. Wynn Macau opened on September 6, 2006 and its second tower – Encore opened on April 21, 2010. For more information on Wynn Macau, visit press.wynnmacau.com.
ABOUT WYNN PALACE
Wynn Palace is the second luxury integrated resort from international resort developer Wynn Resorts in the Macau Special Administrative Region of the People's Republic of China, following the launch of Wynn Macau. Located in the Cotai area, it features a 28-storey hotel with 1,706 exquisitely furnished rooms, suites and villas, versatile meeting facilities, approximately 107,000 square feet of renowned luxury retail, 14 food and beverage outlets, Macau's largest spa, a salon and a pool. The resort also features a variety of entertainment experiences, including the dazzling 8-acre Performance Lake that mesmerizes guests with a choreographed display of water, music and light, the unique SkyCab, an immersive entertainment center, large-scale floral sculptures and an extensive collection of Western and Asian art displays.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Korea Herald
5 hours ago
- Korea Herald
S. Korea, China FMs agree to make upcoming APEC summit 'new turning point' in ties
The top diplomats of South Korea and China agreed Monday to work together to make the upcoming Asia-Pacific Economic Cooperation summit a "new turning point" in bilateral relations, as they held their first telephone call, the South Korean Foreign Ministry said. Foreign Minister Cho Hyun and Chinese Foreign Minister Wang Yi expressed this view during the 45-minute phone conversation, reaffirming their commitment to advance the bilateral strategic cooperative partnership in a "steady and mature" manner, the ministry said in a release. "They agreed to work together to ensure that the upcoming APEC summit in Gyeongju serves as a new turning point in bilateral ties and to deliver tangible outcomes in practical cooperation that can be felt by the peoples of both countries," it said. They also agreed to maintain the positive momentum in bilateral ties through high-level exchanges. The APEC summit is set to take place in the southeastern South Korean city from Oct. 31 to Nov. 1. Chinese President Xi Jinping is widely expected to attend the multilateral meeting. China is the host for next year's APEC summit. Congratulating Cho on his inauguration, Wang expressed a willingness to maintain a close working relationship with him, according to the ministry. Cho, in turn, said he hopes to closely work with Wang to further develop the Seoul-Beijing ties. Cho took office last Monday. He also extended an invitation for Wang to visit South Korea, and Wang responded that he would visit at a mutually convenient time, according to the ministry. (Yonhap)

Korea Herald
7 hours ago
- Korea Herald
Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug
SHANGHAI and HONG KONG, July 28, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that the China National Medical Products Administration (NMPA) has approved XPOVIO ® (selinexor) in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy, a new indication of XPOVIO ®. This approval for XPOVIO ® is based on the data of the BENCH trial, a randomized, controlled, open-label, multicenter Phase III bridging study which compared the safety and efficacy of XVd and Vd regimens in 154 Chinese patients with R/R MM who have received one to three prior lines of therapy. The efficacy and safety data of the BENCH study are generally consistent with those from the global, multicenter, Phase III BOSTON study and met the objectives of the bridging study which showed: Clear superiority of the XVd regimen: compared to the Vd regimen, the XVd regimen demonstrated better clinical efficacy, longer PFS and DOR, a higher ORR, a higher rate of very good partial response (VGPR) or deeper responses and minimal residual disease (MRD) negativity, as well as a trend of prolonged OS. Notable clinical benefits for elderly patients: the study observed particularly notable efficacy in the cohort of elderly patients aged ≥65, validating XPOVIO ® as a better treatment option for this patient population. Prof. Jin Lu, principal investigator of the BENCH study from Peking University People ' s Hospital, said, "MM is the second most common hematologic malignancy. The clinical application of autologous hematopoietic stem cell transplantation (ASCT) and novel agents in the first-line setting have resulted in longer overall survival for patients. However, the condition remains incurable with most patients end up relapsing. As a novel inhibitor of the nuclear export protein that adopts a novel mechanism of action, selinexor was proven by the BENCH study to be significantly efficacious in Chinese patients with MM. This approval for XPOVIO ® is a great news for patients with R/R MM, especially those relapsing for the first time." Prof. Jian Hou, principal investigator of the BENCH study from Shanghai Jiaotong University School of Medicine Affiliated Renji Hospital, commented, "The incidence of MM has been steadily rising year after year. According to the Globocan statistics for 2022, there were 30,300 new cases of MM and 18,662 MM related deaths in China, a figure that highlights an urgent unmet clinical need. Selinexor in combination with bortezomib and dexamethasone incorporates a unique mechanism of action and demonstrated significant efficacy. Moreover, XPOVIO ® does not require intravenous administration, therefore provides clinicians a new treatment strategy that can effectively reduce burden on patients." With a novel mechanism of action, XPOVIO ® is the world's first approved orally-available, selective XPO1 inhibitor, which has already been approved in ten countries and regions in APAC, and has been included in the national insurance schemes in five of these markets (the mainland of China, Taiwan market, Australia, Singapore and South Korea). While bringing XPOVIO ® to more APAC markets, Antengene is also striving to expand the indications of XPOVIO ®. Leveraging the drug's novel mechanism of action, Antengene is currently developing multiple combination regimens of XPOVIO ® for the treatment of various indications including myelofibrosis (MF) and endometrial cancer. About Antengene Antengene Corporation Limited ("Antengene", SEHK: is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets, with the NDA for XPOVIO ® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact:

Korea Herald
7 hours ago
- Korea Herald
Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'
DAEJEON, South Korea, July 28, 2025 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for EYLUXVI ® (code name: ALT-L9), a biosimilar referencing Eylea ® (aflibercept), co-developed with its subsidiary Alteogen Biologics Inc. EYLUXVI ® has been recommended for approval in adult patients for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch [RVO] or central [RVO]), visual impairment due to diabetic macular oedema (DME), and visual impairment due to myopic choroidal neovascularisation (myopic CNV). "We are pleased to receive a positive CHMP recommendation for EYLUXVI ®. This marks a significant milestone for Alteogen," said Soon-Jae Park, PhD, Chief Executive Officer of Alteogen. "We will provide a new, accessible treatment option for patients suffering from devastating ocular diseases such as wet age-related macular degeneration," he added. The positive CHMP opinion was based on the totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package. A randomized, double-masked, parallel group, multicenter Phase 3 study, conducted by Alteogen Biologics, demonstrated equivalent efficacy and comparable safety, immunogenicity, and pharmacokinetics (PK) profiles between EYLUXVI ® and reference aflibercept in patients with wet AMD. Meanwhile, Alteogen licensed the development and commercialization rights for its anti-cancer drug Herceptin ® biosimilar, ALT-L2, for the Chinese market to Qilu Pharmaceutical in 2017. Qilu Pharmaceutical completed its development, obtained approval from Chinese regulatory authorities last year, and is currently marketing the product in China. If approved, EYLUXVI ® will be Alteogen's second commercialized biosimilar product. About the ALT-L9 Phase 3 study The study is a randomized, double-masked, parallel group phase 3 study conducted at 79 centers in 12 countries from June 2022 to February 2024, including follow-up through 52 weeks. 431 participants with wet AMD were randomized 1:1 to receive either ALT-L9 (n = 216) or Eylea® (n = 215). The primary efficacy endpoint of the study was the change from baseline in best corrected visual acuity (BCVA). About Alteogen Alteogen Inc. is a South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as Antibody-Drug Conjugates (ADCs), biobetters, and biosimilars. Alteogen's portfolio includes clinical-stage long-acting therapeutic proteins and next-generation ADCs, developed by its proprietary NexP™-fusion and NexMab™ platform technology, respectively. It also developed a proprietary recombinant human hyaluronidase enzyme utilizing Hybrozyme™ technology, which enables the large volume subcutaneous administration of drugs that are typically administered as an IV infusion. The company was founded in 2008 and listed in KOSDAQ ( For more information, please visit: Contacts: